The UK relative to other single payer-dominated healthcare markets for regenerative medicine therapies.
The UK relative to other single payer-dominated healthcare markets for regenerative medicine therapies.
复制标题
英国相对于其他单一付款人主导的再生医学治疗医疗保健市场。
DOI：
--
复制
发表时间：
2012
影响因子：
2.7
通讯作者：
David J. Williams
中科院分区：
文献类型：
--
作者：
James B. Rose;David J. Williams
多年来，英国一直被企业（包括总部位于英国的企业）视为推出创新医疗技术产品的第二市场。从历史上看，这是由于其国民保健服务（NHS）的采用速度缓慢。国民保健服务被认为受到成本控制，高度分散和缺乏战略激励措施，以解决其作为一个市场的关键缺陷。加拿大和瑞典提供了在单一支付者主导的市场中提供医疗保健服务的不同运营模式的例子，因此，它们具有不同的市场特征。总之，这些经济体代表了医疗保健市场的一个重要细分市场，主要是医疗保健市场。本报告审查了这些经济体再生医学产品的市场进入障碍，并试图评估即将到来的英国医疗改革对再生医学行业的影响。
The UK has for many years been considered by businesses, including those based in the UK, as at best a second market for the launch of innovative medical technology products. Historically, this has been attributed to the slow pace of adoption in its National Health Service (NHS). The NHS is perceived to be subject to cost containment, high levels of fragmentation and a lack of strategic incentives to resolve its key failings as a market. Canada and Sweden offer examples of different operating models of healthcare delivery in a single payer-dominated market, and as a consequence, have evolved with different market characteristics. Together, these economies represent an important subsection of healthcare markets that are predominantly publically funded. This report examines the barriers to market entry for regenerative medicine products in these economies and attempts to evaluate the upcoming UK healthcare reforms in terms of impact on the regenerative medicine industry sector.